- Prof. Brown is a leading researcher in Transcranial Magnetic Stimulation (“TMS”) and currently serves as President of the Clinical TMS Society.
- His work explores how brain stimulation therapies can be enhanced through neuroplasticity-focused medications, including D-cycloserine, a component of NRx’s investigational drug NRX‑101.
- Brown previously received funding from the Defense Advanced Research Projects Agency (“DARPA”) to study treatments for military personnel suffering from Post-Traumatic Stress Disorder (“PTSD”).
- NRx is investigating a treatment approach combining ketamine, TMS, and hyperbaric oxygen in patients with PTSD and depression, with trials planned through its HOPE Therapeutics clinic network.
- The appointment reflects NRx’s evolving strategy to integrate neuroscience research and clinical deployment in treatments for severe central nervous system disorders.
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has appointed neurostimulation researcher Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer, bringing a prominent academic voice in brain stimulation therapies into its leadership ranks (https://ibn.fm/zaQzM).
The company is developing treatments targeting central nervous system disorders including suicidal depression and Post-Traumatic Stress Disorder (“PTSD”). Brown’s appointment signals a deeper focus on combining pharmacological approaches with device-based therapies designed to modify neural…
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN